LAG-3 is identified as a potential biomarker for SCLC, aiding in patient stratification for ICI therapy. Higher LAG-3 expression in SCLC correlates with improved survival and increased immune activity ...

Checkpoint inhibitors are an anticancer drug that indirectly attacks tumors. They depend on infusions of antibodies to block proteins called immune checkpoints. Specifically, they target one of three ...

More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag into registrational testing in one of the most important oncology disease ...

Immutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well tolerated across all dose levels IMP761 data and Phase I results will be presented at the EULAR ...

Immutep reports no adverse events in Phase I trial of IMP761, a LAG-3 agonist for autoimmune diseases, with more data expected in 2025. Immutep Limited has released promising initial safety data for ...

A molecular “snapshot” of a protein can be critical to understanding its function. Scientists at Stanford and NYU have published and investigated a new structure of the protein LAG-3 which could ...

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure. The drugmaker found a fixed-dose combination of Keytruda and an anti-LAG-3 ...

LAG-3 exerts its inhibitory function by undergoing phase separation with the CD3ε subunit of the TCR/CD3 complex; Enhancing the cis-proximity between LAG-3 and TCR through a LAG-3/TCR bispecific ...

Immutep (IMMP) announces new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 binds to its main ligand MHC Class II, also known as HLA Class II in humans.

Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therapeutics, including Immutep’s anti-LAG-3 ...